The Nanotech Revolution in Drug Delivery

THE NANOTECH REVOLUTION IN DRUG DELIVERY

Market Drivers: Clinical Benets Unlocking the value of Pharmas existing compounds Demographics Opportunities: The Creation of New DDS Companies New Products are Already on the Market Market Growth Technologies: Nanoparticles Nanocystals Polymer Therapeutics Liposomes What are they? Availability Key Players How are they applied to drug delivery?

A new value paradigm is taking shape in the drug delivery market. Nanostructured delivery techniques will shape the future of drug delivery.

The Nanotech Revolution in Drug Delivery

Nanotechnology-enabled drug delivery systems (DDS) over the next ve years are forecast to dramatically reshape the way existing drugs are delivered. The growing range of nanotechnology enabled drug delivery methods is poised to change the way new compounds are formulated, and to extend the life cycle of existing compounds. By 2012 nano-enabled DDS will capture over a 15% share of the market from its current potion of 4%. But that is just the beginning. After 2015, nano-enabled technologies will take the lions share of the market, making up nearly 90% of the drug delivery market--a complete transformation of the way DDS are formulated.

Establishing a New Paradigm in Pharmaceuticals

toxicity, more specic targeting and reduced cost of treatments. At present many drugs fail clinical trials because the compound cannot be delivered to the site where it is needed without having some interaction with the human body on the way. The result can range from triggering a severe immune system response to toxic side effects. Getting the active compound to where it is needed, and effectively delivering it is one of the holy grails in the treatment of diseases ranging from inammations to cancer.

Unlocking the value of Pharmas existing compounds

The global pharmaceutical industry has been developing compounds for over a century, but many of these never get to market. The acceptance of new drug formulations is expensive and slow, taking up to 15 years to obtain accreditation of new drug formulas with no guarantee of success. Compounds

Market Drivers:
Clinical Benefits of Nanotechnology in Drug Delivery
The benets of nanotech-based drug DDS will be dramatic for both doctors and patients, providing lower drug

Page 1

Cientifica Ltd 2007

www.cientifica.com

The Nanotech Revolution in Drug Delivery

THE NANOTECH REVOLUTION IN DRUG DELIVERY
which are highly effective, such as Taxol for the treatment of cancer, are also toxic to healthy cells, and current delivery methods are unable to target just the diseased cells, leading to side effects. As a result, drug formulation companies are looking to make use of these already in-use drugs and nding better ways of delivering them to their targets. At present, several hundred billion dollarsworth of existing compounds which cannot be delivered properly are sitting in IP vaults unused, and the industry is keen to unlock and exploit this valuable intellectual property. New drug delivery compounds will also extend the product and patent lifecycles of drugs, allowing the creation of New Chemical Entities (NCEs) via reformulation of existing and/or orphaned compounds, and subsequent creation of value for shareholders and consumers. Many drugs are poorly soluble, a major problem when the human body is 70% water. In general, poor water solubility correlates with slow dissolution rate, and decreasing the particle size increases the surface area, which leads to an increase in dissolution rate. However, it seems likely that, as the large pharmaceutical companies explore the wide variety of drugs that may benet from new nanoparticle-based delivery techniques, there will be some consolidation of methods into a few generally useful ones and opportunities for smaller companies will start to dry up.

New Products are Already Coming through Clinical Trials

Nano-enabled DDS have already hit the market with a number of FDA approved compounds. Initially these have primarily been with the polymer Polyethylene glycol (PEG) in which PEG is conjugated with peptides and proteins but this will soon change and novel nanostructures and nanoparticles will begin to take a larger share of the new nanoenabled DDS. As an example Nucryst is in Phase 2 clinical trials with silver nanoparticles for drug delivery to treat atopic dermatitis, and Accusphere is in Phase 1 clinical trials with a nanoparticle that treats solid tumors while the US FDA approved the rst inhalable version of insulin in 2006. The novel alternative to injectable insulin for the treatment of type-1 and type-2 diabetes was developed by Pzer with Sano-Aventis and Nektar Therapeutics, and is marketed as "Exubera".

Opportunities:
The Creation of New DDS Companies
The global pharmaceutical industry is increasingly relying on outsourcing innovation in every business area, from clinical trials to drug discovery. The result has been a healthy market for acquisitions of companies which have a proven technology, and this has in turn stimulated more and more venture backed start ups in the bio and pharma space. The development of nano-enabled DDS has followed this pattern, and has not been restricted to the large pharmaceutical companies. Many new companies have been launched that have developed novel methods for exploiting nanotechnologies in drug delivery, and many more are in incubation. Nano DDS companies are popping up all around the world, in Europe, the US and across Asia, for example Nanocarrier (Japan) CeramiSphere Pty Ltd (Australia) Nanovindex Ltd (UK) Aquanova (Germany) Insert Therapeutics (USA) Biophan (USA) Capsulution (Germany) Flamel Technologies (France)

Market Growth
Unlike other markets in which nanotechnology is merely projected to have an impact, nano-enabled DDS already represents a $3.39 billion market. But we are just seeing the tip of the iceberg as the technology shifts from polymer therapeutics through to truly innovative approaches enabled by our control of materials on the same scale at which nature works. By 2012 the total market for nanotechnology-enabled drug delivery will rise to $26 billion, representing a compound annual growth rate of 37% over the next ve years, and after 2012 things become really interesting, the value of these nano-enabled compounds will sky rocket, reaching $220 billion by 2015. Beyond just the economics, the use of nanoparticles will transform medical treatment, allowing practitioners to use drugs to target specic areas of the body, without side effects or concerns over toxicity since lower doses could be used, concentrating the effect where needed. The utility of nanoparticles in drug delivery to improve human health and quality of life is potentially enormous. This White Paper presents four technologies that will change the paradigm of the drug delivery market, including:

Page 2

Cientifica Ltd 2007

www.cientifica.com

The Nanotech Revolution in Drug Delivery

Value of Nanotechnology Based DDS 2006-2015

THE NANOTECH REVOLUTION IN DRUG DELIVERY

Nanoparticles (including inorganic, polymer and solid lipid nanoparticles) Nanocrystals Polymer Therapeutics (including polymer drugs, polymer drug conjugates, polymer micelles and dendrimers) Liposomes For more detailed information please see The Nanoparticle Drug Delivery Market Report

$250,000

$200,000

US$ Millions

$150,000

$100,000

Polymer Therapeutics Dendrimers Other Nanostructures Nanoparticles

$50,000

$0 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Year

Source: The Nanoparticle Drug Delivery Report

The Nanoparticle Drug Delivery Market Report

Nanoparticle drug delivery system by therapeutics Nanoparticle drug delivery system by technology Nanoparticle drug delivery system by delivery method
The report will give Pharma investors a comprehensive understanding on the impact of nanotechnologies on the pharmaceutical market and companies, which include companies that are producing nanomaterials/ technologies to enable better drug delivery compounds (drug delivery company) and companies that are using nano-enabled formulations to enhance drug delivery (drug formulation company). The report will provide an in-depth discussion on recent developments of nanoparticle-enabled drug delivery systems (DDS) and future opportunities. It is tailored for investors who plan to invest in the pharmaceutical industry with an eye towards how nanoparticle drug delivery technology will impact the economics of the pharmaceutical market. The information includes business summaries, technology core competencies, how nanoparticle adds value for investors in drug delivery companies, comercialization strategies, intellectual property and available markets. There are 58 case studies on nanoparticle DDS listed in the report according to 3 categories: Delivery Method/Routes of administration Oral administration Transdermal delivery Injectable delivery Topical delivery Nasal/pulmonary delivery Implantable delivery Therapeutics Cancer therapy Vaccines Antibody DNA-based therapy Technology Nanoparticulate encapsulation Dendrimer-based targeted therapeutics technology Liposomes nanotechnology Nanotube technologies Nanoparticles coating technology Silica-chitosan nanocomposite Nanosome technology Nanosuspension technology Nanocrystal technology Nanoshell technology Polymer therapeutics There are totally 58 nanoparticle drug delivery platforms/technolologies studied in the report. There are totally 61 companies refered in the report, which includes 38 drug formulation companies and 23 drug delivery companies. For each company a full prole is provided. USA takes up 70% of the total companies involved in nanoparticleenhanced drug delivery technology.

Available Applications Of Nanoparticle In Drug Delivery 1. Acromegaly 2. Age-related macular degeneration 3. Anesthetic 4. Antibodies 5. Antiemetic 6. Antiinfectives, oncologics, cardiac drugs and others 7. Atopic dermatitis 8. B-cell Chronic Lymphocytic/Non-Cancer therapy 9. Chronic kidney disease 10. Eating disorders 11. End stage renal failure Lymphoma/Intrathecal therapy of lymphomatous meningitis 12. Febrile neutropenia 13. Fungal infections 14. Glioblastoma 15. Hepatitis A, C 16. HIV/AIDS 17. Inuenza 18. Immunodeciency syndrome 19. Immunosuppressant 20. Kaposi sarcoma 21. Hodgkins Chronic fatigue immune dysfunction (myalgic encephalomyelitis; ME) 22. Lipid regulation 23. Menopausal therapy 24. Multiple sclerosis 25. Rheumatoid arthritis and Crohns disease

Page 3

Cientifica Ltd 2007

www.cientifica.com

THE NANOTECH REVOLUTION IN DRUG DELIVERY

The Nanotech Revolution in Drug Delivery

Availability: In February 2005, the first nanoparticulate drug delivery product, Abraxane for the treatment of breast cancer was launched by Abraxis Oncology, a division of American Pharmaceutical Partners, Inc. Key Players: American Pharmaceutical Partners (USA) CritiTech (USA) Novax Inc (USA) RTP Pharma (USA) Sheffield Pharmaceuticals Nanosphere Eiffel Technologies Biosante Pharmaceuticals Advectus Life Sciences (USA) Copernicus Therapeutics (USA)

Nanoparticles
What are they?

Nanoparticles can be divided into three groups: Inorganic nanoparticles Solid lipid nanoparticles Polymer nanoparticles Inorganic nanoparticles is the generic term for several nanoparticles including for example metal oxide- and non-oxide ceramics, metals, calcium phosphate, gold, silicate and magnetic nanoparticles. So called nanoshells combine various inorganic elements or materials. They typically have a silicon core, which is sealed in an outer metallic cover. Polymer nanoparticles involve various natural or biocompatible synthetic polymers. They include rationally designed macromolecular drugs, polymerdrug and polymer-protein conjugates, polymeric micelles containing covalently bounded drugs, and polyplexes for DNA delivery. Polymer nanoparticles can be divided into nanospheres, which build a continuous polymer matrix

and can be referred as drug sponges and nanocapsules, which consist of a polymer layer enclosing a uid-lled cavity and are mimicking liposomes. Solid lipid nanoparticles combine the advantages but avoiding the disadvantages of other colloidal carriers have attracted increasing attention in recent years, and are regarded as an alternative carrier system to traditional colloidal systems, such as emulsions, liposomes and polymeric microparticles and nanoparticles.
How are they applied to drug delivery?

Nanoparticles are widely used in drug delivery where they can increase drug solubility and, additionally, can lead to controlled release and/or drug targeting. They are used in anti-cancer treatment, genedelivery, asthma inhalers, hormone delivery through the skin, drug delivery through the eye and in oral and vaccine delivery systems. A lot of companies employ nanoparticles in anti-cancer treatment.

Page 4

Cientifica Ltd 2007

www.cientifica.com

The Nanotech Revolution in Drug Delivery

THE NANOTECH REVOLUTION IN DRUG DELIVERY
Availability: The first United States approval of a product produced incorporating the NanoCrystal technology occurred in August 2000. Key Players: Elan Pharmaceuticals (USA) SkyePharma (UK)

Nanocrystals
What are they?
Increasing the active surface area is the key to many applications of nanotechnologies, from improving automotive and industrial catalysts to improving the uptake of poorly soluble drugs in the human body. Nanocrystals are ground in special mills and the resulting drugs can be applied intravenously as nanosuspensions or bronchially through an inhaler. This small size enhances the surface/volume-ratio and bioavailability of almost insoluble pharmaceuticals. drug substance using a proprietary, wet-milling technique. The resulting particles of the drug are stabilized against agglomeration by surface adsorption of selected GRAS (Generally Regarded As Safe) stabilizers. The result is an aqueous dispersion of the drug substance that behaves like a solution, which can be processed into nished dosage forms for all routes of administration. The size of the particles allows for safe and effective passage through capillaries. NanoCrystal technology represents both an enabling technology for evaluating new chemical entities that exhibit poor water solubility and also a valuable tool for optimizing the performance of established drugs. NanoCrystal technology is of particular benet for drugs with poor solubility in water. The process is also useful for moderately soluble drugs when a high concentration of drug in a low volume of uid is desired.

How are they applied to drug delivery?

For poorly water-soluble drug compounds, grinding them into nanoscale crystals increases the surface area of the compounds, which leads to an increase in dissolution rate. In one of the best known cases, Elan Pharmaceuticals NanoCrystal technology, particles are small particles of drug substance, typically less than 1000 nanometers (nm) in diameter, which are produced by milling the

Page 5

Cientifica Ltd 2007

www.cientifica.com

The Nanotech Revolution in Drug Delivery

THE NANOTECH REVOLUTION IN DRUG DELIVERY
Availability: The first poly (ethylenglycol) (PEG)ylated proteins were approved by regulatory authorities for routine clinical use in the early 1990s. Key Players: StarPharma (USA) Enzon (USA) Teva Pharmaceuticals (Israel)

Polymer Therapeutics
What is it?
Polymer therapeutics differ from particle shaped drug delivery systems in their dimensions. They are molecular units with diameters of a few nanometres and can be subdivided into four groups: Polymer drugs Polymer drug conjugates Polymer micelles Dendrimers Early designs for a polymer therapeutic system involved attaching a water-soluble polymer to a drug through a selected linker molecule. Trapping low molecular weight drugs as polymer conjugates not only temporarily inactivates the drug, but also restricts their uptake by cells to endocytosis (the process whereby cells absorb material such as proteins from the outside by engulng it with their cell membrane). As high molecular weight macromolecules of the drugs are unable to diffuse passively into cells, they are 'engulfed' as membrane-encircled sacs called vesicles, in which intracellular enzymes then set to work to release the drug. This means that the polymer-drug conjugate should be able to circulate longer in the body, potentially without the toxic side-effects associated with many drugs. With the appropriate biodegradable linker, and/or a cell-specic targeting group, it should be possible to deliver the drug direct to the target site.

How is it applied to drug delivery?

A drug can be covalently bound to the four groups above. They differ from other drug-delivery systems in which a drug is encapsulated or solubilised and are more akin to new chemical entities since chemical conjugation occurs (i.e the combined polymer and drug behave as a compound different from either component).

Page 6

Cientifica Ltd 2007

www.cientifica.com

The Nanotech Revolution in Drug Delivery

THE NANOTECH REVOLUTION IN DRUG DELIVERY
Availability: In 1995, the first liposome-encapsulated form of the anti-cancer drugs doxorubicin and daunrubicin are approved for human use. Key Players: SkyePharma (UK) Ortho Biotech (USA) Anosys (USA) Azaya Therapeutics (USA) LiPlasome Pharma (USA)

Liposomes
What are they?
Liposomes are small spheres that have a lipid layer that surrounds an active pharmaceutical ingredient. Their basic components are amphiphilic molecules, which spontaneously form liposomes in aqueous ambiance. Hydrophilic ends of the globular bilayers point to the waterside, hydrophobic ends are oriented bilateral to the centre of the layer.

the membrane) they can be (indiscriminately) delivered past the lipid bilayer. Liposomes can also be designed to deliver drugs in other ways. Liposomes that contain low (or high) pH can be constructed such that dissolved aqueous drugs will be charged in solution. As the pH naturally neutralizes within the liposome the drug will also be neutralized, allowing it to freely pass through a membrane. Another strategy for liposome drug delivery is to target endocytosis events. Liposomes can be made in a particular size range that makes them viable targets for natural macrophage phagocytosis. These liposomes may be digested while in the magrophage's phagosome, thus releasing its drug. Liposomes can also be decorated with opsonins and ligands to activate endocytosis in other cell types.

How are they applied to drug delivery?

Because a liposome can encapsulate an aqueous solution with a hydrophobic outer membrane, hydrophilic solutes cannot pass through the lipids. So, lipsomes can carry both hydrophobic molecules (its outer membrane) and hydrophilic molecules (the inner aqueous core). The liposome delivers its contents to the appropriate site by having its lipid bilayer fuse with bilayers of the cell membrane. By making liposomes in a solution of DNA or drugs (which would normally be unable to diffuse through

Page 7

Cientifica Ltd 2007

www.cientifica.com

The Nanotech Revolution in Drug Delivery

THE NANOTECH REVOLUTION IN DRUG DELIVERY

The Nanoparticle Drug Delivery Market Report ----- Table of Contents

TABLE OF EXHIBITS.......................................................... 9 EXECUTIVE SUMMARY.................................................... 13 AIM, SCOPE AND ORGANIZATION OF REPORT. 13 CIENTIFICA NANOTECHNOLOGY MODEL. 17 Definitions of Nanotechnologies 18 Major Assumptions 18 BACKGROUND. 20 MARKET FORECAST & OVERVIEW.............................. 21 INTRODUCTION TO THE MARKETS ............................ 30 NANOPHARMACEUTICALS. 30 NANOTECHNOLOGY IN DRUG DELIVERY. 31 NANOBIOTECHNOLOGY IN DRUG DELIVERY. 32 OTHER APPLICATIONS FOR NANOMATERIALS IN THE MEDICAL AND PHARMACEUTICAL SECTOR 32 TRENDS AND NEEDS. 33 ROADMAP. 34 NANOTECHNOLOGY INFLUENCE IN PHARMACEUTICAL VALUE CHAIN. 35 ANALYTICAL TECHNIQUES FOR NANOPARTILE DRUG DELIVERY. 39 Properties 39 Production Of Nanoparticles.39 Measuring Dispersion Of Nanoparticles. 40 Analysis Of Carrier Systems 41 NANOPARTICLES AS DRUG CARRIERS.42 What Can Nanoparticles Do In Drug Delivery. 42 Overview On The Types Of Nanoparticles In Drug Delivery. 44 The First Nanoparticle Drug Delivery System Reaches The Market 47 Present And Future Applications 48 PROJECTED PRODUCT PIPELINE FOR NANOPARTICLE IN DRUG DELIVERY MARKET. 51 Overview Of Nanoparticle Drug Delivery System (DDS) In Various Applications 51 Available Applications Of Nanopartcile In Drug Delivery. 52 DRUG DELIVERY CHALLENGES -- WHY DRUG DELIVERY & WHY NANOPARTICLES........................... 54 THE NEED FOR BETTER DRUG THERAPY. 54 THE NEED FOR DRUG SOLUBILITY. 54 THE NEED FOR SITE-SPECIFIC AND ORGAN-SPECIFIC IN FUNCTION. 55 DRIVERS AND OPPORTUNITIES FOR NANOPARTICLE DRUG DELIVERY....................................................... 56 THE AIM OF DRUG TARGETING. 56 REASONS WHY THE DRUG DELIVERY MARKET IS RAPIDLY EXPANDING. 56 MARKET DRIVERS FOR ENHANCED DRUG DELIVERY. 57 THE ADVANTAGES OF USING POLYMERIC NANOPARTICLES (PNPS) IN DRUG DELIVERY. 58

EXPANDING GOVERNMENTAL FUNDING DRIVES THE NANOBIOTECHNOLOGY MARKET. 59 HOW DRUG COMPANIES ARE REACTING TO THIS EXPANSION. 60 FUTURE BARRIERS AND CHALLENGES...................... 62 BIG PHARMACEUTICAL COMPANIES RELUCTANT TO INVEST IN UNTRIED TECHNOLOGIES. 62 LACK OF REGULATORY CASE LAW. 62 LONG ADMISSION PROCEDURES INCLUDING FOR EXAMPLE SEVERAL CLINICAL TRIALS. 63 A NEED FOR RAPID SCREENING METHODS. 63 SCALABILITY OF NANOPARTICLE PRODUCTION. 63 AN URGENT NEED FOR ANALYTICAL METHODS. 63 A NEED FOR THE INVESTIGATION OF FURTHER NANOPARTICLES.63 THE POTENTIAL TOXICITY OF ENGINEERED NANOPARTICLES IS AN UNSOLVED ISSUE AND STILL NEEDS TO BE DEALT WITH. 64 THE FUTURE OF NANO AND BIO COLLABORATIONS IS PROMISING. 67 NANOPARTICLE ADDED VALUE IN DRUG DELIVERY.......................................................................................... 69 CASE STUDY -- UNIVERSITY OF MICHIGANS NANOPARTICLE-BASED PAIN RELIEF STUDY FOR MILITARY BATTLEFIELD USE. 69 CASE STUDY -- ACUSPHERES HYDROPHOBIC DRUG DELIVERY SYSTEM (HDDS) FOR REFORMULATION OF HYDROPHOBIC DRUGS. 70 CASE STUDY -- IMARXS HYDROPLEX PLATFORM FOR DELIVERING HYDROPHOBIC DRUGS. 72 CASE STUDY ALPHARXS NANOPARTICLE DRUG DELIVERY PLATFORM FOR ANTIBIOTIC DRUGS. 75 CASE STUDY CYTRXS RNAI NANOPARTICLE DELIVERY TECHNOLOGY FOR RNAI THERAPEUTICS. 76 INVESTING IN NANOPARTCLE-ENABLED DRUG DELIVERY INDUSTRY........................................................ 78 CASE STUDY NANOTHERAPEUTICS COMMERCIALISATION STRATEGY. 78 Business Summary.78 Technology Core Competency. 78 Commercialisation Strategy.78 Available Market.79 CASE STUDY HOW CAN NANOVINDEXS NANOPARTICLE HYDROGEL COMPOSITES ADD VALUE FOR DRUG DELIVERY INVESTORS. 79 Business Summary.79 Technology Core Competency. 79 How Nanoparticles Add Value For Investors In Drug Delivery Company.79 Comercialization Strategy. 80 Available Market.80 CASE STUDY -- KEYSTONE NANOS MOLECULAR DOTS (MDS) COMMERCIALISATION STRATEGY. 80 Business Summary.80 Technology Core Competency. 80 How Nanoparticles Add Value For Investors In Drug Delivery Company.80 Commercialisation Strategy.81 Available Market.81

Page 8

Cientifica Ltd 2007

www.cientifica.com

The Nanotech Revolution in Drug Delivery

THE NANOTECH REVOLUTION IN DRUG DELIVERY
Intellectual Property.81 CASE STUDY NANOCARRIERS PROTEINS NANOENCAPSULATION SEEKING OUT BIG BIOTECH BUSINESS. 81 Business summary.81 Technology Core Competency. 81 How Nanoparticles Add Value For Investors In Drug Delivery Company.82 Commercialisation Strategy.85 Available Market.86 CASE STUDY -- NANOBIOMAGNETICS BUSINESS MODEL FOR ORGAN-ASSISTING-DEVICE (OAD) TECHNOLOGIES. 86 Business Summary.86 Technology Core Competency. 87 How Nanoparticles Add Value For Investors In Drug Delivery Company.87 Commercialisation Strategy.88 Intellectual Property.89 CASE STUDY HOW CAN AVIDIMER THERAPEUTICS AVIDIMERS PLATFORM TECHNOLOGY ADD VALUE FOR DRUG DELIVERY INVESTORS. 89 Business Summary.89 Techonology Core Competency. 90 How Nanoparticles Add Value For Investors In Drug Delivery Company.91 Commercialisation Strategy.92 CASE STUDY -- CAPSULUTIONS COMMERCIALISATION STRATEGY FOR LBL-TECHNOLOGY-BASED DRUG DELIVERY SYSTEMS. 92 Business Summary.92 How Nanoparticles Add Value For Investors In Drug Delivery Company.92 Commercialisation Strategy.92 CASE STUDY -- ACCESS PHARMACEUTICALS PRODUCT PIPELINE FOR COBALAMIN- MEDIATED DISEASE TARGETING. 93 Business Summary.93 Technology Core Competency. 93 How Nanoparticle Add Value For Investors In Drug Delivery Company.93 CASE STUDY - AZAYA THERAPEUTICS PRODUCT PIPELINE FOR PROTEIN STABILIZED LIPOSOME (PSL) NANOTECHNOLOGY. 94 Business Summary.94 Technology Core Competency. 95 Commercialisation Strategy.95 NANOPARTICLE DRUG DELIVERY SYSTEM BY DELIVERY METHOD/ROUTES OF ADMINISTRATION........................................................................................ 98 DELIVERY METHOD. 98 ORAL ADMINISTRATION. 99 Case Study -- Access Pharmaceuticals Cobalamin Mediated Disease Targeting 99 Case Study Nanotherapeutics Nanoparticle Oral Applications 103 Case study SoluBests Solumer Technology Platform 103 TRANSDERMAL DELIVERY. 106 Case Study -- Biophan Technologies Transdermal Patches By Using Halloysite Nanotubes Technology. 106 Case Study -- The Interstitial NanoSystems Transdermal Nanoparticle Delivery.108 INJECTABLE DELIVERY. 110 Case Study -- Biophan Technologies Nanomagnetic Guided Drug Delivery 110 Case Study -- Nanobiotixs NanoBiodrugsTM. 114 TOPICAL DELIVERY. 115 Case Study -- Starpharmas VivaGel 115 Case Study Nanotherapeutics NanoDRY; NanoCOAT and NanoQUAD Drug Delivery Systems 116 INHALED/NASAL/PULMONARY DELIVERY. 118 Case Study -- Interstitial NanoSystems Pulmonary Nanoparticle Delivery. 119 IMPLANTABLE DELIVERY. 119 Case Study -- Biophan Technologies Nanomagnetic Drug Delivery: Drug-Eluting Implanted Devices 120 Case Study -- NanoBioMagnetics Organ-AssistingDevice (OAD) Technologies. 125 NANOPARTICLE DRUG DELIVERY SYSTEM BY THERAPEUTICS.................................................................. 127 THERAPY. 127 CANCER THERAPY. 128 Case Study -- Nanocarriers Micellar Nanoparticles And Key Delivery Systems.130 Case Study -- Abraxis BioSciences Nanoparticle Albumin Bound (nabTM) Technology Platform. 135 Case Study -- Abraxis BioSciences Abraxane 136 Case Study -- Access Pharmaceuticals, Inc.s Nanoparticle Aggregate Drug Delivery Technology. 137 Case Study -- Access Pharmaceuticals ProLindac 138 Case Study -- Advance Nanotechnologies Nanoparticle Composites Drug Delivery System. 140 Case Study -- BioAlliance Pharmas Nanoparticlebased Transdrug Drug Delivery Platform. 142 Case Study -- Cornerstone Pharmaceuticals Emulsiphan Nanoparticle Tumor Targeting Technology. 143 Case Study -- Insert Therapeutics Nanoparticle Mediated Drug Delivery System.151 Case Study -- Keystone Nanos Molecular Dots (MDs) Drug Delivery Technology.152 Case Study -- Magforce Nanotechnologies MagForce Nanoparticles 157 Case Study -- Tempo Pharmaceuticals Nanocell Technology. 158 Case Study -- Aphios Corporations TaxosomesTM. 159 VACCINES. 160 Case Study -- Biosante Pharmaceuticals Calcium Phosphate Nanoparticles (CAP)-based Technology. 160 Case Study -- NanoMed's Nanotemplate Engineering Technology. 163 Case Study -- Novavaxs Micellar Nano Particles (MNPs), Novasome Paucilamellar Vesicles And Virus-Like Particle (VLP) Technology. 166 ANTIBODY. 167 Case Study -- Ablynxs Nanobody Platform.167 Case Study NanoViricides Targeted Anti-Viral Therapeutics Platform.169 DNA BASED THERAPY. 172 Case Study -- Introgen Therapeutics Nanoparticle Drug Delivery Technology Platform. 173 Case Study -- Asklpios BioPharmaceutical Inc.s Biological Nano Particles (BNP) Platform. 176

Page 9

Cientifica Ltd 2007

www.cientifica.com

The Nanotech Revolution in Drug Delivery

THE NANOTECH REVOLUTION IN DRUG DELIVERY
Case Study -- Copernicus Therapeutics DNA Nanoparticles 180 Case Study -- Calando Pharmaceuticals Targeted Polymeric Nanoparticle Delivery Systems And Sirna Design. 184 Case Study -- Epeius Biotechnologies Targeted Delivery System (TDS) Technology.188 Case Study -- Intradigms Nanoparticle-Based Delivery System 190 Case Study -- Flamel Technologies Medusa Delivery Platform. 194 Case Study -- Novosom AGs SMARTICLES and CAGICLES Technology. 198 Case Study -- Transgenex Nanobiotechs SiPlex Technology. 200 NANOPARTICLE DRUG DELIVERY SYSTEM BY TECHNOLOGY..................................................................... 202 NANOPARTICULATE ENCAPSULATION. 202 Case Study -- Aquanovas Nanoparticulate Encapsulation Technology. 202 Case Study -- Bio Delivery Sciences Internationals Bioral Encochleation Drug Delivery Technology.205 Case Study -- Capsulutions LBL-Technology-based Drug Delivery Systems.207 Case Study -- Ceramispheres Encapsulation Technology. 209 Case Study Genesegues Targeted Nanocapsule Technology. 210 Case Study iCeuticas Encapsulated Organic Nanoparticles (EON) Platform.212 Case Study NutraLeases Nanoencapsulation Technology.213 THE DENDRIMER-BASED TARGETED THERAPEUTICS TECHNOLOGY. 220 Case Study -- Avidimer Therapeutics Avidimers 220 Case Study -- Dendritic Nanotechnologies Inc. (DNT)S Priostar Dendrimer Nanotechnology. 223 LIPOSOMES NANOTECHNOLOGY. 226 Case Study -- Azaya Therapeutics Protein Stabilized Liposome (PSL) Nanotechnology Platform 228 Case Study -- LiPlasome Pharmas Liposome-based Drug Delivery Platform.229 NANOTUBE TECHNOLOGIES. 231 Case Study -- Biophan Technologies Halloysite Nanotube Technologies.231 Case Study -- NanoCytes Nanotube Technology-based Drug Delivery System. 232 NANOSHELL TECHNOLOGY. 233 Case Study -- Nanospectra Biosciences AuroLase Cancer Therapy.233 NANOPARTICLES COATING TECHNOLOGY. 235 Case Study -- Cytimmunes Colloidal Gold Nanoparticle-Based Delivery Platform. 235 SILICA-CHITOSAN NANOCOMPOSITE. 238 Case Study -- ISTNs Silica-Chitosan Nanocomposties For Peptic Ulcer Treatment 238 NANOCRYSTAL TECHNOLOGY. 238 Case Study -- Elans NanoCrystal Technology. 238 NANOSOME TECHNOLOGY. 241 Case Study -- Molecular Therapeutics Nanosome Platform 241 NANOSUSPENSION TECHNOLOGY. 243 Case Study -- Baxter BioPharma Solutions NANOEDGE Dispersion Technology.243 POLYMER THERAPEUTICS. 244 Case Study Labopharms Polymeric Nano-Delivery System 244 Case Study -- Intezyne Technologies IVECT Drug Delivery Platform (DDP).248 Case Study -- Insert Therapeutics Nanoparticle Mediated Drug Delivery System.250 APPENDIX 1: LIST OF NANOPARTICLE DRUG DELIVERY PLATFORMS/TECHNOLOGIES ....................... 255 APPENDIX 2: NANOPARTICLES IN DRUG DELIVERY PRODUCTS ON THE MARKET OR IN CLINICAL PHASE 1/2/3.................................................................. 258 APPENDIX 3: OVERVIEW OF NANOPARTICLE APPLICATIONS IN DRUG DELIVERY................................. 261 APPENDIX 4: DRUG DELIVERY COMPANY - COMPANIES WHO PRODUING NANOPARTICLES/ TECHNOLOGIES ENABLE BETTER DRUG DELIVERY COMPOUNDS .............................................................. 269 APPENDIX 5: DRUG FORMULATION COMPANY COMPANIES WHO USING NANOPARTICLEENABLED FORMULATIONS TO ENHANCE DRUG DELIVERY............................................................................. 281

Ordering Information
Orders may be placed via e-mail or Cientica website: www.cientica.com, Table of Contents can be found online. We accept Credit Cards (Visa/Mastercard) or Wire transfers. The report will be dispatched in secure PDF format.

About Cientifica Twenty Years Of Nanotech

Cientca is the world's largest and best established nanotechnology information and consultancy company. With a global network of partners, Cientica provides information and research to thousands of clients worldwide. Cientica analysts look beyond the hype and behind the numbers to provide relevant and focussed business intelligence. Cientica provides a suite of consulting services to a diverse group of clients, from oil conglomerates and the semiconductor industry, to SMEs and start-ups. Equally at home in the board room and the lab, our offering includes bespoke reports, strategic development and quarterly market forecasts as well as technology and HSE briengs. We recognize that

Page 10

Cientifica Ltd 2007

www.cientifica.com

The Nanotech Revolution in Drug Delivery

THE NANOTECH REVOLUTION IN DRUG DELIVERY
your needs are unique and always tailor our services accordingly. * Market analysis & forecasting * Strategic technology consulting * Competitor benchmarking * Customer / supplier awareness * Risk assessment * Policy and legislative hotspots * Investment and acquisition studies * Product penetration and market positioning * Supplier identication and evaluation

Nanotech Revolution in Drug Delivery This new white paper analyses the impact of nanoparticles on the drug delivery market by focusing on ve groups of nanoparticles that are projected to capture a majority of the market. www.cientica.com

THE NANOTECH REVOLUTION IN DRUG DELIVERY

For more details on The Nanoparticle Drug Delivery Market Report contact us at: Cientifica Ltd 7 Devonshire Sq Cutlers Gardens London EC2M 4YH UK Tel +44 (0)207 377 8480 Fax +44 (0)207 990 8410 email website info@cientifica.com www.cientifica.com

Page 11

Cientifica Ltd 2007

www.cientifica.com